Search - tctmd.com

Displaying 61 - 80 of 91

Sort: Relevancy | Date

Presentation Fellows 2017

Antithrombin Therapy for the Interventionalist

Presenter: Manish A. Parikh, David J. Cohen

April 07, 2017

News Conference News ACC 2017

Prioritizing Impella Support May Boost Cardiogenic Shock Survival, Pilot Study Suggests

Todd Neale

March 22, 2017

Presentation TCT 2016

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Hitinder S. Gurm

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Gennaro Giustino

November 01, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

Presentation Fellows 2016

Antithrombin Pharmacology for the Interventionalist

Presenter: Jeffrey W. Moses, David J. Cohen

April 16, 2016

Presentation Fellows 2016

Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist

Presenter: Gary S. Mintz, David J. Cohen

April 16, 2016

News Daily News

AVB Absorb: Seguridad, Eficacia y Trombosis del Stent a Estudio en 2 Nuevos Análisis

Michael O'Riordan

March 30, 2016

News Daily News

Absorb BVS: Safety, Efficacy, and Stent Thrombosis Tackled in Two New Analyses

Michael O'Riordan

March 30, 2016

News Daily News

Absorb BVS：两项新研究解决了安全性、有效性和支架血栓问题

Michael O'Riordan

March 30, 2016

News Daily News

SYNTAX at 5 Years: CABG Holds Cost-Effectiveness Edge Over PCI

August 20, 2014

News Daily News

SYNTAX al cabo de 5 Años: CABG es Más Rentable que la PCI

August 20, 2014

News Daily News

5年时SYNTAX：CABG比PCI更具成本效益优势

August 20, 2014

Presentation

Cost-Effectiveness of PCI with DES vs Bypass Surgery for Patients with 3-Vessel or Left Main CAD

Presenter: David J. Cohen

August 11, 2014

News Daily News

与华法林或阿司匹林相比，阿哌沙班更具成本效益

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban es Rentable comparado con Warfarina o Aspirina

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Caitlin E. Cox

February 26, 2014

News Daily News

Early QOL Advantage of CABG Over PCI for Diabetic Patients Disappears After 2 Years

L.A. McKeown

October 15, 2013

News Daily News

La CABG es Más Rentable a Largo Plazo en Pacientes Diabéticos con Enfermedad Multivaso

Yael L. Maxwell

January 09, 2013

Advertisement

Antithrombin Therapy for the Interventionalist

Prioritizing Impella Support May Boost Cardiogenic Shock Survival, Pilot Study Suggests

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Antithrombin Pharmacology for the Interventionalist

Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist

AVB Absorb: Seguridad, Eficacia y Trombosis del Stent a Estudio en 2 Nuevos Análisis

Absorb BVS: Safety, Efficacy, and Stent Thrombosis Tackled in Two New Analyses

Absorb BVS：两项新研究解决了安全性、有效性和支架血栓问题

SYNTAX at 5 Years: CABG Holds Cost-Effectiveness Edge Over PCI

SYNTAX al cabo de 5 Años: CABG es Más Rentable que la PCI

5年时SYNTAX：CABG比PCI更具成本效益优势

Cost-Effectiveness of PCI with DES vs Bypass Surgery for Patients with 3-Vessel or Left Main CAD

与华法林或阿司匹林相比，阿哌沙班更具成本效益

Apixaban es Rentable comparado con Warfarina o Aspirina

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Early QOL Advantage of CABG Over PCI for Diabetic Patients Disappears After 2 Years

La CABG es Más Rentable a Largo Plazo en Pacientes Diabéticos con Enfermedad Multivaso

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content